Did You Know...
...that the Slinky toy was the result of a failed attempt by engineer Richard James to produce an antivibration device for ship instruments? His goal was to develop a spring that would instantaneously counterbalance the wave motion that rocks a ship at sea. Instead, he developed the Slinky.
PatentStorm News
Make the Most of Our Site
See this month's Top Inventors and Most Cited Patents.
Stay on top of the latest innovations by subscribing to an RSS feed.
Registered users: Manage your profile.
| Number | Title | Issue Date |
| 8133514 | Carbon-substituted diketopiperazine delivery systems Compositions useful in the delivery of active agents are provided. These delivery compositions include (a) an active agent; and (b) a carrier of at least one mono-C-substituted or di-C-substituted diketopiperazine. Methods for preparing these compositions and admini... | 03/13/2012 |
| 8119593 | Method of treating diabetes type 2 by metformin and an ultrarapid acting insulin Disclosed herein are improved methods of treating hyperglycemia with a combination of an ultrarapid acting insulin and insulin glargine comprising prandial administration of the ultrarapid insulin, and administration of a first dose of insulin glargine within 6 hour... | 02/21/2012 |
| 7468360 | Therapeutic amides and related compounds Disclosed herein is a compound having a structure: Therapeutic methods, compositions, and medicaments relating thereto are also disclosed. ... | 12/23/2008 |
| 7439372 | Therapeutic compounds A compound having a structure is disclosed herein. Compositions, medicaments, and therapeutic methods related thereto are also disclosed. ... | 10/21/2008 |
| 7439386 | Therapeutic substituted cyclopentanones Compounds are disclosed herein comprising or a pharmaceutically acceptable salt, or a metabolite or a prodrug thereof; wherein a dashed line indicates the presence or absence of a bond; Y, A, an... | 10/21/2008 |
| 7435746 | 5-thiopiperdinyl prostaglandin E analogs A compound comprising or a pharmaceutically acceptable salt or a prodrug thereof is disclosed herein. Y and R are described in detail herein A compound having an ω chain comprising ... | 10/14/2008 |
| 7429615 | Cyclohexyl prostaglandin analogs as EP-receptor agonists The invention relates to the use of novel cyclohexyl analogues of E-type prostaglandins as EP4 agonists, in general, and, in particular as ocular hypotensives. The cyclohexyl analogues used in accordance with the invention are represented by the following... | 09/30/2008 |
| 7429669 | Therapeutic compounds Disclosed herein are compounds of the formula or salts or bioisosteres thereof. Therapeutic methods, medicaments, and compositions related thereto are also disclosed. ... | 09/30/2008 |
| 7427685 | Therapeutic substituted cyclopentanes Therapeutic compounds according to one of the structures below are disclosed herein. ... | 09/23/2008 |
| 7427614 | Prostaglandin analogs Compounds comprising or a pharmaceutically acceptable salt or a prodrug thereof is disclosed herein. A, X, J, E, and Z are as described herein. These compounds are useful for treating diseases. ... | 09/23/2008 |
| 7422110 | Titration/compliance pack with increasing doses A titration package and method for enabling compliance with a regime of changing dosage of medication over a period of time includes a backing having an array of receivers with the array including a plurality of columns and a plurality of rows. A plurality of sets o... | 09/09/2008 |
| 7419994 | 4-(substituted cycloalkylmethyl) imidazole-2-thiones, 4-(substituted cycloalkenylmethyl) imidazole-2- thiones, 4-(substituted cycloalkylmethyl) imidazol-2-ones and 4-(substituted cyloalkenylmethyl) imidazol-2-ones and related compounds Compounds of Formula 1 where X is S and the variables have the meaning defined in the specification are specific or selective to alpha2B and/or alpha2C adrenergic receptors in ... | 09/02/2008 |
| 7405240 | Substituted cyclopentanes or cyclopentanones as therapeutic agents The compounds disclosed herein are useful for treating glaucoma, ocular hypertension, and baldness. ... | 07/29/2008 |
| 7399868 | 4-(Heteroaryl-methyl and substituted heteroaryl-methyl)-imidazole-2-thiones acting as alpha2 adrenergic agonists Compounds of Formula 1 where the variables have the meaning defined in the specification are agonists of alpha2 adrenergic receptors. Several compounds of the disclosure are specific or selective to alpha2B | 07/15/2008 |
| 7390829 | Alpha-2 adrenergic agonists A compound is disclosed herein comprising or a pharmaceutically acceptable salt or a prodrug thereof; wherein R is OH or NH2. Methods, compositions, and medicaments related thereto... | 06/24/2008 |
| 7390318 | Needleless microprotrusion elastoplast system A needleless microprotrusion system for infusion of a medicament into a patient includes a plurality of microprotrusions having a length sufficient to penetrate a stratum corneum of the patient. A chemodenervating agent is disposed for delivery by the microprotrusio... | 06/24/2008 |
| 7384648 | Implant device with a retinoid for improved biocompatibility An implant device is provided which incorporates a retinoid for improving the biocompatibility of the device in tissue. The device may be bioerodible for the purpose of systemically or locally releasing a therapeutic agent in tissue or it may be a permanent implant ... | 06/10/2008 |
| 7364570 | Controlled volume injection/aspiration device A controlled volume injection/aspiration device includes a syringe having a body for containing a medicament, a needle and a piston slidably disposed within the body. A shell is provided for receiving the syringe body and a plunger rack is disposed within the shell.... | 04/29/2008 |
| 7358269 | 2-((2-Thioxo-2,3-dihydro-1H-imidazol-4-yl)methyl)-3,4-dihydronapthalen-1(2H)-one A compound of the formula or a pharmaceutically acceptable salt thereof, is disclosed herein. Methods and compositions related thereto are also disclosed. ... | 04/15/2008 |
| 7345077 | 4-(substituted cycloalkylmethyl) imidazole-2-thiones, 4-(substituted cycloalkenylmethyl) imidazole-2-thiones, 4- (substituted cycloalkylmethyl) imidazol-2-ones and 4- (substituted cycloalkenylmethyl) imidazol-2-ones and related compounds Compounds of Formula 1 where X is S and the variables have the meaning defined in the specification are specific or selective to alpha2B and/or alpha2C adrenergic receptors in ... | 03/18/2008 |
| 7335803 | Methods and compositions for modulating alpha adrenergic receptor activity Methods and compositions for the treatment of pain and intraocular pressure. Particularly disclosed are new compositions for the treatment of chronic pain, glaucoma and methods for their use. ... | 02/26/2008 |
| 7332526 | Compositions and methods comprising prostaglandin-related compounds and trefoil factor family peptides for the treatment of glaucoma with reduced hyperemia Compositions, methods, and pharmaceutical products related to prostaglandin-related compounds and trefoil factor family peptides are disclosed herein. Of particular interest are compositions and methods useful for the treatment of glaucoma with a reduced occurrence ... | 02/19/2008 |
| 7326716 | Treatment of inflammatory bowel disease The present invention provides a method of treating inflammatory bowel disease which comprises administering to an animal having ocular hypertension or glaucoma therapeutically effective amount of a piperidinyl prostaglandin E analog. ... | 02/05/2008 |
| 7326698 | Prostaglandin analogs Compounds comprising or a pharmaceutically acceptable salt or a prodrug thereof is disclosed herein. A, X, J, and E are as described herein. These compounds are useful for treating diseases. ... | 02/05/2008 |
| 7323485 | 4-(substituted cycloalkylmethyl) imidazole-2-thiones, 4-(substituted cycloalkenylmethyl) imidazole-2-thiones, 4-(substituted cycloalkylmethyl) imidazol-2-ones and 4-(substituted cycloalkenylmethyl) imidazol-2-ones and related compounds Compounds of Formula 1 where X is S and the variables have the meaning defined in the specification are specific or selective to alpha2B and/or alpha2C adrenergic re... | 01/29/2008 |
| 7323477 | 7-((1H-imidazol-4-yl)methyl)-5,6,7,8-tetrahydroquinoline A compound having a structure or a pharmaceutically acceptable salt, or a prodrug thereof is disclosed herein. Therapeutic methods, compositions, and medicaments related thereto are also disclosed. ... | 01/29/2008 |
| 7323463 | Combination of brimonidine and timolol for topical ophthalmic use Disclosed are pharmaceutical compositions comprising brimondine and timolol for topical ophthalmic delivery and a method of treatment comprising administering said composition when indicated for glaucoma and associated conditions such as elevated intraocular pressur... | 01/29/2008 |
| 7323591 | Substituted cyclopentanes or cyclopentanones as therapeutic agents Therapeutic compounds, methods, and compositions are disclosed herein. These compounds have prostaglandin EP2 activity, and are useful to treat and/or prevent glaucoma and/or ocular hypertension in a mammal. ... | 01/29/2008 |
| 7320976 | Combination of brimonidine and timolol for topical ophthalmic use Disclosed are pharmaceutical compositions comprising brimondine and timolol for topical ophthalmic delivery and a method of treatment comprising administering said composition when indicated for glaucoma and associated conditions such as elevated intraocular pressur... | 01/22/2008 |
| 7314890 | Sulfonamides The present invention provides wherein R1 is selected from the group consisting of C1-C10 alkoxy, OH and NR4R5; R2 | 01/01/2008 |
| 7312238 | Nonsedating α-2 agonists The present invention provides an α-2A/α-1A selective agonist that includes a compound represented by Structure 1 or a pharmaceutically acceptable salt, ester, amide, sterioisomer or racemic mixture thereof. The present invention further provides a pharmaceutical ... | 12/25/2007 |
| 7297679 | Cyclosporin compositions A composition comprising from about 0.001% to about 0.4% cyclosporin A, a surfactant, and an oil having a specific gravity from 0.8 to 0.95 is disclosed herein. ... | 11/20/2007 |
| 7294716 | Process for preparing isomerically pure prodrugs of proton pump inhibitors Synthetic methods for preparing isomerically pure N-arylsulfonyl derivatives of proton pump inhibitors which include a substituted benzimidazole nucleus are shown by the synthetic schemes and experimental description. ... | 11/13/2007 |
| 7288520 | Cyclosporin compositions A composition is disclosed herein comprising from about 0.001% to about 0.4% cyclosporin A, castor oil, and a surfactant selected from the group consisting of alcohol ethoxylates, alcohols, alkyl glycosides, alkyl polyglycosides, alkylphenol ethoxylates, amine oxide... | 10/30/2007 |
| 7276476 | Cyclosporin compositions A composition comprising from 0.001% to about 0.4% cyclosporin A, a surfactant, and an oil selected from the group consisting of anise oil, clove oil, cassia oil, cinnamon oil, and combinations thereof, wherein said composition is an ophthalmically acceptable emulsi... | 10/02/2007 |
| 7273883 | Prostaglandin EP4 antagonist Disclosed herein are methods and compositions related to compound 1 or a pharmaceutically acceptable salt, or a prodrug thereof (all of which are referred to hereafter, collectively or individually, as “compoun... | 09/25/2007 |
| 7244768 | Compositions and methods comprising prostaglandin related compounds and trefoil factor family peptides for the treatment of glaucoma with reduced hyperemia Compositions, methods, and pharmaceutical products related to prostaglandin-related compounds and trefoil factor family peptides are disclosed herein. Of particular interest are compositions and methods useful for the treatment of glaucoma with a reduced occurrence ... | 07/17/2007 |
| 7235586 | Cyclopentane heptan(ene)oic acid, 2-thiocarbamoyloxy and 2-carbamoyloxy compounds as therapeutic agents The invention relates to the use of cyclopentane heptan(ene)oic acid, 2-thiocarbamoyloxy and carbamoyloxy as therapeutic agents e.g. as ocular hypotensives. The compounds used in accordance with the invention are represented by the following formula I: | 06/26/2007 |
| 7230032 | Calcium blockers to treat proliferative vitreoretinopathy Glutamate causes migration and proliferation of retinal pigment epithelium and/or glial cells, and glutamate antagonists can prevent, treat or reduce retinal pigment epithelium and/or glial migration and the subsequent development of proliferative vitreoretinopathy.... | 06/12/2007 |
| 7223746 | Omega cycloalkyl 17-heteroaryl prostaglandin E2 analogs as EP2-receptor agonists The invention relates to the use of derivatives of E-type prostaglandins as EP2 agonists, in general, and, in particular as ocular hypotensives. The PGE derivatives used in accordance with the invention are represented by the following formula I: | 05/29/2007 |
